{"id":79623,"date":"2023-09-21T18:12:24","date_gmt":"2023-09-21T18:12:24","guid":{"rendered":"https:\/\/www.merckconnect.ca\/en\/?post_type=mhh-sticky-footer&#038;p=79623"},"modified":"2026-01-23T17:54:00","modified_gmt":"2026-01-23T17:54:00","slug":"keytruda-psp-safety","status":"publish","type":"mhh-sticky-footer","link":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/","title":{"rendered":"Keytruda PSP Safety"},"content":{"rendered":"<div class=\"mhh-sticky-footer-panel mhh-sticky-footer-panel--1c829b31323e951a1737148838dcb00c\">\n    <button class=\"mhh-sticky-footer-panel__expand-button\" \n            data-event-name=\"accordion_click\" \n            data-design-module=\"indication\"\n            data-design-category=\"accordion\"\n            data-design-label=\"expand\">\n                    <svg\n            xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n            fill=\"currentColor\"\n            viewBox=\"0 0 16 16\"\n            >\n            <path\n            d=\"M8 4a.5.5 0 0 1 .5.5v3h3a.5.5 0 0 1 0 1h-3v3a.5.5 0 0 1-1 0v-3h-3a.5.5 0 0 1 0-1h3v-3A.5.5 0 0 1 8 4z\"\/>\n            <\/svg>\n                <span>EXPAND<\/span>\n        <\/button>\n    <div class=\"mhh-sticky-footer-inner\">\n    \n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color mhh-mcn-v1-paragraph--right  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c9b7fee009ae47c0eee6dad873e522d1\"><a href=\"https:\/\/www.merck.ca\/en\/wp-content\/uploads\/sites\/20\/2021\/04\/KEYTRUDA-PM_E.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">KEYTRUDA\u00ae Product Monograph<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading  has-border-color has-has-red-border-color-border-color has-white-color has-text-color  has-object-object-font-size mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--6006cd6a51fb7eaced698cc34aec461d\" style=\"background-color:#6cc04a\">                                                                                              <strong>IMPORTANT SAFETY INFORMATION<\/strong><\/h3>\n\n    <\/div>\n<\/div>\n\n\n<div class=\"mhh-sticky-footer-expanded-panel mhh-sticky-footer-expanded-panel--8851977f8adf5ba16ae615c50be6e745 \" dir=\"ltr\">\n    <div class=\"mhh-sticky-footer-expanded-panel__inner\">\n        <div class=\"mhh-sticky-footer-expanded-panel__close-button-wrapper\">\n            <button class=\"mhh-sticky-footer-expanded-panel__close-button\">\n                        <svg\n                xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n                fill=\"currentColor\"\n                viewBox=\"0 0 16 16\"\n            >\n                <path\n                d=\"M4.646 4.646a.5.5 0 0 1 .708 0L8 7.293l2.646-2.647a.5.5 0 0 1 .708.708L8.707 8l2.647 2.646a.5.5 0 0 1-.708.708L8 8.707l-2.646 2.647a.5.5 0 0 1-.708-.708L7.293 8 4.646 5.354a.5.5 0 0 1 0-.708z\"\/>\n            <\/svg>\n                                    <\/button>\n        <\/div>\n        <div class=\"mhh-sticky-footer-expanded-panel__body\">\n            \n\n<h3 class=\"wp-block-heading  has-border-color has-has-red-border-color-border-color has-white-color has-text-color  has-object-object-font-size mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--6362775ca7e05d15acaa1130085c2813\" style=\"background-color:#6cc04a\">                                                                                                                                          <strong>IMPORTANT SAFETY INFORMATION<\/strong><\/h3>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--e58fb50415a379180727dede16684c9f mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--74283deedbb5cb6543b8e0ae430fec8d mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--487b30b6ba67d1110c60f07956d9b273\">KEYTRUDA\u00ae&nbsp;has been issued marketing authorization&nbsp;<strong>with conditions<\/strong>, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for KEYTRUDA\u00ae, please refer to Health Canada\u2019s Notice of Compliance with conditions &#8211; drug products web site: <a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/notice-compliance\/conditions.html\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/notice-compliance\/conditions.html<\/a>.<\/p>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1bf2304d056831629b5c6ecf628ba35e\">KEYTRUDA\u00ae&nbsp;is indicated for:<\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--0a225fdcb0ef1746a1262e05ed9f42a9 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment, as monotherapy, of adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL) who have failed autologous stem cell transplant (ASCT), or who are not candidates for multi-agent salvage chemotherapy and ASCT. An improvement in overall survival has not yet been established.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment, as monotherapy, of adult and pediatric patients with refractory primary mediastinal B-cell lymphoma (PMBCL), or who have relapsed after 2 or more lines of therapy. An improvement in survival or disease-related symptoms has not been established.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumours who are ineligible for or have elected not to undergo cystectomy. The indication is authorized based on tumour complete response rate and durability of response.    <\/li>\n\n<\/ul>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7ec929ced83684c33844e524ded3e456\">KEYTRUDA\u00ae&nbsp;has been issued marketing authorization&nbsp;<strong>without conditions<\/strong>&nbsp;for:<\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f279dcf193b60e355df99dd9cbefba61\"><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--e2d72967560b23159758c810da615ea6 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. Subjects with BRAF V600 mutant melanoma may have received prior BRAF inhibitor therapy.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    First-line treatment, as monotherapy, of adult patients with metastatic non-small cell lung carcinoma (NSCLC) or Stage III disease where patients are not candidates for surgical resection or definitive chemoradiation, expressing PD-L1 [tumour proportion score (TPS) \u22651%] as determined by a validated test, with no EGFR or ALK genomic tumour aberrations.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with metastatic non-squamous NSCLC in combination with pemetrexed and platinum chemotherapy, with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with metastatic squamous NSCLC in combination with carboplatin and either paclitaxel or nab-paclitaxel, with no prior systemic chemotherapy treatment for metastatic NSCLC.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with metastatic NSCLC as monotherapy, whose tumours express PD-L1 (TPS) \u22651%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have received authorized therapy for these aberrations prior to receiving KEYTRUDA\u00ae.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Adjuvant treatment of adult patients with Stage IB (T2a \u22654 cm), II, or IIIA NSCLC who have undergone complete resection and platinum-based chemotherapy.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with locally advanced unresectable or mUC, as monotherapy, who are not eligible for any platinum-containing chemotherapy. An improvement in survival or disease-related symptoms has not been established.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with locally advanced or metastatic urothelial carcinoma, as monotherapy, who have disease progression during or following platinum-containing chemotherapy or within 12 months of completing neoadjuvant or adjuvant platinum-containing chemotherapy.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC), in combination with enfortumab vedotin, with no prior systemic therapy for mUC.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC) in combination with axitinib, with no prior systemic therapy for metastatic RCC.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with advanced (not amenable to curative surgery or radiation) or metastatic RCC in combination with lenvatinib, with no prior systemic therapy for metastatic RCC.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Adjuvant treatment, as monotherapy, of adult patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment, as monotherapy, of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) as determined by a validated test.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment, as monotherapy, of adult and pediatric patients with unresectable or MSI-H or dMMR solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.    <\/li>\n\n<\/ul>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--62cc0234c98b7f232378e343f18db3f3 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment, in combination with lenvatinib, of adult patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior platinum-based systemic therapy and are not candidates for curative surgery or radiation.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    First-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression [combined positive score (CPS) \u22651] as determined by a validated test.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    First-line treatment of metastatic or unresectable recurrent HNSCC in combination with platinum and fluorouracil (FU) chemotherapy, in adult patients.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    First-line treatment, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumours express PD-L1 (CPS \u22651) as determined by a validated test.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    First-line treatment, in combination with fluoropyrimidine- and platinum-containing chemotherapy, of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    First-line treatment, in combination with platinum and fluoropyrimidine based chemotherapy, of adult patients with locally advanced unresectable or metastatic carcinoma of the esophagus.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment, in combination with chemotherapy, of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 (CPS \u226510), as determined by a validated test.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with high-risk, early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS \u22651) as determined by a validated test, in combination with chemotherapy with or without bevacizumab.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment, in combination with gemcitabine-based chemotherapy, of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC).    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d0dae21503fff95544a1de235ae13970\"><strong><span style=\"text-decoration: underline\">Clinical use:<\/span><\/strong><\/p>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--0563e574fa0432df58bec0457bce07d6\">The safety and efficacy of KEYTRUDA\u00ae<sup> <\/sup>has not been established for pediatric patients with conditions other than melanoma (Stage IIB, IIC, or III), relapsed or refractory cHL, relapsed or refractory PMBCL, or unresectable or metastatic MSI-H or dMMR solid tumours.<\/p>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--27ca7e9ac7699196310a0642d9e6921d\">Geriatrics (\u226565 years of age): No overall differences in safety or efficacy were reported between elderly patients (65 years and over) and younger patients (less than 65 years) for KEYTRUDA\u00ae monotherapy. No overall differences in efficacy were reported between elderly patients (65 years and over) and younger patients (less than 65 years) for KEYTRUDA\u00ae combination therapy. Limited safety and efficacy information is available for KEYTRUDA\u00ae in cHL \u226565 years of age (n=20).<\/p>\n\n\n\n<p class=\"has-black-color has-text-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--34882a8a3ca0d7b1b2c18d4bc5044392\"><span style=\"text-decoration: underline\"><strong>Relevant warnings and precautions:<\/strong><\/span><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--30c4fa4048c829a4ba8f37e311b53690 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Immune-mediated adverse reactions, including severe and fatal cases:    <\/li>\n\n<\/ul>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--c5f874e48851fa2b3fd4a1ce0f64579d mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Pneumonitis    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Colitis    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Hepatitis    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Nephritis and renal dysfunction    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Endocrinopathies including adrenal insufficiency, hypophysitis, type 1 diabetes mellitus and thyroid disorders    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis    <\/li>\n\n<\/ul>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--0460f596e9251cdb142b87ae3a1fe32c mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Other immune-mediated adverse events including uveitis, arthritis, myositis, encephalitis, sarcoidosis, myasthenic syndrome\/myasthenia gravis, vasculitis, Guillain-Barr\u00e9 syndrome, hemolytic anemia, pancreatitis, myelitis, hypoparathyroidism, gastritis, myocarditis, sclerosing cholangitis, aplastic anemia, and exocrine pancreatic insufficiency    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Solid organ transplant rejection    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Use in combination with axitinib for RCC    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Use with thalidomide analogue and dexamethasone in multiple myeloma    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Allogeneic stem cell transplant after and before treatment    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Severe infusion-related reactions    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Teratogenic toxicity    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Women of childbearing potential should use highly effective contraception and take active measures to avoid pregnancy during treatment and for at least 4 months after the last dose    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Advise women not to breastfeed during treatment and for at least 4 months after the last dose    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Patients with hepatic impairment    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Renal impairment    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Driving and operating machinery    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Monitoring requirements    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Pediatrics    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Geriatrics    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ced8e7f4ee7dfeaadef1eb3ee2b043d8\"><strong>For more information:<\/strong><\/p>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--cb757d341cea740ad2e26491d115e1c9\">Consult the KEYTRUDA\u00ae&nbsp;<a href=\"https:\/\/www.merck.ca\/en\/wp-content\/uploads\/sites\/20\/2021\/04\/KEYTRUDA-PM_E.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Product Monograph<\/a>&nbsp;for important information regarding adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling us at <span class=\"no-text-breaking\">1-800-567-2594<\/span> or by email at medinfocanada@merck.com.<\/p>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--051cf49790008e73d9f05f7b4312f6d4\">ALK=anaplastic lymphoma kinase; BRAF=v-raf murine sarcoma viral oncogene homologue B1; EGFR=epidermal growth factor receptor; PD-L1=programmed death ligand 1; PMBCL=primary mediastinal large B-cell lymphoma.<\/p>\n\n        <\/div>\n    <\/div>\n<\/div>\n\n\n\n<div class=\"mhh-sticky-footer-safety-content\">\n    <\/div>\n","protected":false},"template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"promomats_ca_generated_at":0,"promomats_ca_screen_sizes":["Desktop","Mobile"],"footnotes":""},"mh-depends-on":[],"class_list":["post-79623","mhh-sticky-footer","type-mhh-sticky-footer","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Keytruda PSP Safety | Merck Connect Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Keytruda PSP Safety | Merck Connect Canada\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck Connect Canada\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-23T17:54:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/\",\"name\":\"Keytruda PSP Safety | Merck Connect Canada\",\"isPartOf\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#website\"},\"datePublished\":\"2023-09-21T18:12:24+00:00\",\"dateModified\":\"2026-01-23T17:54:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.merckconnect.ca\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Keytruda PSP Safety\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#website\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/\",\"name\":\"Merck Connect Canada\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.merckconnect.ca\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#organization\",\"name\":\"Merck Connect Canada\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png\",\"contentUrl\":\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png\",\"width\":1284,\"height\":331,\"caption\":\"Merck Connect Canada\"},\"image\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Keytruda PSP Safety | Merck Connect Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/","og_locale":"en_US","og_type":"article","og_title":"Keytruda PSP Safety | Merck Connect Canada","og_url":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/","og_site_name":"Merck Connect Canada","article_modified_time":"2026-01-23T17:54:00+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/","url":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/","name":"Keytruda PSP Safety | Merck Connect Canada","isPartOf":{"@id":"https:\/\/www.merckconnect.ca\/en\/#website"},"datePublished":"2023-09-21T18:12:24+00:00","dateModified":"2026-01-23T17:54:00+00:00","breadcrumb":{"@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-psp-safety\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckconnect.ca\/en\/"},{"@type":"ListItem","position":2,"name":"Keytruda PSP Safety"}]},{"@type":"WebSite","@id":"https:\/\/www.merckconnect.ca\/en\/#website","url":"https:\/\/www.merckconnect.ca\/en\/","name":"Merck Connect Canada","description":"","publisher":{"@id":"https:\/\/www.merckconnect.ca\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckconnect.ca\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.merckconnect.ca\/en\/#organization","name":"Merck Connect Canada","url":"https:\/\/www.merckconnect.ca\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png","contentUrl":"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png","width":1284,"height":331,"caption":"Merck Connect Canada"},"image":{"@id":"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer\/79623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer"}],"about":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/types\/mhh-sticky-footer"}],"version-history":[{"count":31,"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer\/79623\/revisions"}],"predecessor-version":[{"id":84577,"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer\/79623\/revisions\/84577"}],"wp:attachment":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/media?parent=79623"}],"wp:term":[{"taxonomy":"mh-depends-on","embeddable":true,"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mh-depends-on?post=79623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}